Law firm Maurice Blackburn has successfully defended a consumer law and intellectual property lawsuit brought over its use of a replica of the famous Fearless Girl statue by US financial services giant State Street Global Advisors.
Two patent attorneys being sued by boutique IP firm Pizzeys Patent and Trade Mark Attorneys have hit back against claims they misused confidential information to poach clients, arguing the terms of the non-compete restraint in their employment contracts were “unclear”, “unreasonable” and “unenforceable”.
Two high stakes lawsuits brought by a2 Milk Company against rival dairy producers over the use of a2 as a trade mark are “very likely” to reach resolution next week, a court has heard.
Two law firms locked in a courtroom battle over their ‘C’ trade marks made up of concentric circles will move to mediation after one of the firms files “significantly more” evidence about their reputation in Melbourne, a court has heard.
IP Australia has rejected e-commerce giant Amazon’s patent application for a method of allocating resources in virtual computers, finding the patent’s claims were “nothing more than a scheme for scheduling work” and were not a manner of manufacture.
Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after an unjustified court injunction prevented the release of a generic version of the top-selling drug, an appeals court has heard.
US pharmaceutical giant Merck Sharp & Dohme has taken Sandoz to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Janumet and Januvia.
A French geographical indication body has triumphed in its opposition to a bid to trade mark the name ‘Chateau Roquehort’ for dairy products, with a delegate finding that Australians would wrongly associate the name with blue cheeses from France.
US biotech company Gen-Probe’s bid for the removal of rival Beckman Coulter’s ‘Access’ trade marks will be heard alongside its appeal of a ruling from the Trade Marks Office denying the company’s bid to expand its ‘Open Access’ trade mark to Australia.
The High Court will decide whether the Full Court was wrong to overturn a $26.3 million judgment for Danish drug maker H Lundbeck in its long-running patent battle with generic drug maker Sandoz over the patent for blockbuster antidepressant Lexapro.